



Received: 26-04-2026
Accepted: 06-05-2026

ISSN: 2583-049X

Letter to the Editor

Ogilvie Syndrome can Mimic Intestinal Pseudo-Obstruction in m.3243A>G Carriers

Josef Finsterer

Department of Neurology, Neurology & Neurophysiology Center, Vienna, Austria

Corresponding Author: **Josef Finsterer**

Letter to the Editor

We read with interest the article by Liu *et al.* about a 24-year-old patient with MELAS syndrome (mitochondrial encephalopathy with lactic acidosis and stroke-like episodes) due to the m.3243A>G variant in the MT-TL1 gene with a heteroplasmy rate of 61% and TRPM3-related neurocognitive impairment due to the heterozygous c.2878G>T variant in the TRPM3 gene [1]. The patient presented clinically with confusion, generalized tonic-clonic seizures, intestinal pseudo-obstruction (IPO), lactic acidosis, and bilateral lesions of the basal ganglia, cerebellum, and thalamus [1]. She benefited significantly from jejunal decompression [1]. The study is interesting, but some questions remain.

First, it was not clearly distinguished between the clinical manifestations attributable to the m.3243A>G variant and those attributable to the TRPN3 variant [1]. Assigning clinical manifestations to one variant or the other is crucial, as treatment, course, and outcome may differ. TRPN3-related neurodevelopmental disorder manifests clinically with intellectual disability, developmental delay, epilepsy, and hypotonia [2]. Mutations in the TRPM3 gene are classified as gain-of-function mutations that lead to overactive, calcium-permeable cation channels [2].

Secondly, MELAS is diagnosed according to either the Hirano or the Japanese criteria [3, 4]. According to the Japanese criteria, MELAS is diagnosed when there are signs of encephalopathy associated with dementia or epilepsy, stroke-like episodes (SLE) in early childhood, and biochemical evidence of mitochondrial dysfunction, such as acidosis and the presence of ragged-red fibers in muscle biopsy [4]. According to the Hirano criteria, MELAS is diagnosed when SLE occur before the age of 40 and there are seizures or dementia, lactic acidosis or ragged-red fibers, normal early childhood development, recurrent headaches, or recurrent vomiting [3]. For these reasons, MELAS syndrome should not be diagnosed in the index patient. Since the index patient had no history of a stroke-like episode (SLE), which is the pathognomonic feature of MELAS, the clinical diagnosis remains unclear. Given that the patient presented with bilateral symmetrical lesions of the basal ganglia and thalamus, a diagnosis of Leigh syndrome should be considered rather than MELAS.

Third, IPO is not a rare phenotypic feature in MELAS. It is attributed to the involvement of smooth muscle cells with respiratory chain dysfunction, leading to reduced peristalsis or even complete cessation of intestinal contraction activity [5]. IPO has been described in several patients with the m.3243A>G variant [6, 7, 8, 9].

Fourth, no immunohistological or biochemical analyses were performed on the jejunal sample obtained during decompression surgery. Since the reduced contractility of the smooth muscle cells is most likely due to smooth muscle cell involvement, it would have been interesting to know whether the functions of the respiratory chain complexes are also reduced in the jejunal smooth muscle cells.

Fifth, it cannot be ruled out that the IPO was caused by treatment with tranquilizers as antiepileptic drugs. This phenomenon is known as Ogilvie syndrome and can also be caused by drugs with strong anticholinergic properties or those that affect the autonomic nervous system. In addition to benzodiazepines, clozapine and olanzapine can also trigger Ogilvie syndrome [10].

In summary, patients with MELAS should meet the Hirano or Japanese criteria. Symmetrical lesions of the basal ganglia, thalamus, and cerebellum are more indicative of Leigh syndrome than MELAS. IPO is not a rare manifestation of the m.3243A>G variant but has been repeatedly described. Before attributing IPO in an m.3243A>G carrier to the underlying gene defect, Ogilvie syndrome must be ruled out.

Declarations**Ethical Approval:** Not applicable.**Consent to Participation:** Not applicable.**Consent for Publication:** Not applicable.**Funding:** None received.**Availability of Data and Material:** All data are available from the corresponding author.**Completing Interests:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.**Author Contribution:** JF was responsible for the design and conception, discussed available data with coauthors, wrote the first draft, and gave final approval. SM: contributed to literature search, discussion, correction, and final approval.**Acknowledgements:** None.**Keywords:** MELAS, mtDNA, m3243A>G, Intestinal Pseudo-Obstruction, Seizures**References**

1. Liu Q, Yang L, Liu P, Wang X, Peng K, Liu Q, *et al.* A case of delayed acute intestinal pseudo-obstruction after MELAS crisis in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes. *Front Med (Lausanne)*, Jan 15, 2026; 13:1760790. Doi: 10.3389/fmed.2026.1760790
2. Dymont D, Lines M, Innes AM. TRPM3-Related Neurodevelopmental Disorder. 2023 Feb 23. In: Adam MP, Bick S, Mirzaa GM, *et al.*, editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle, 1993-2026. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK589387/>
3. Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, DeVivo DC, *et al.* Melas: An original case and clinical criteria for diagnosis. *Neuromuscul Disord.* 1992; 2(2):125-135. Doi: 10.1016/0960-8966(92)90045-8
4. Yatsuga S, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T, *et al.* Taro Matsuoka for MELAS Study Group in Japan. MELAS: A nationwide prospective cohort study of 96 patients in Japan. *Biochim Biophys Acta*, May 2012; 1820(5):619-624. Doi: 10.1016/j.bbagen.2011.03.015
5. Li JY, Hsieh RH, Peng NJ, Lai PH, Lee CF, Lo YK, *et al.* A follow-up study in a Taiwanese family with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes syndrome. *J Formos Med Assoc*, Jul 2007; 106(7):528-536. Doi: 10.1016/S0929-6646(07)60003-5
6. Ng YS, Feeney C, Schaefer AM, Holmes CE, Hynd P, Alston CL, *et al.* Pseudo-obstruction, stroke, and mitochondrial dysfunction: A lethal combination. *Ann Neurol*, Nov 2016; 80(5):686-692. Doi: 10.1002/ana.24736

7. Suzuki J, Iwata M, Moriyoshi H, Nishida S, Yasuda T, Ito Y. Gastro-intestinal Involvement in m.3243A>G-associated Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like Episodes. *Intern Med*, Mar 1, 2018; 57(5):771. Doi: 10.2169/internalmedicine.9632-17
8. Gagliardi D, Mauri E, Magri F, Velardo D, Meneri M, Abati E, *et al.* Can Intestinal Pseudo-Obstruction Drive Recurrent Stroke-Like Episodes in Late-Onset MELAS Syndrome? A Case Report and Review of the Literature. *Front Neurol*, Jan 31, 2019; 10:38. Doi: 10.3389/fneur.2019.00038
9. Kawano Y, Taniguchi A, Narita Y, Kagawa K, Harada T, Shindo A. Effective Management of Chronic Intestinal Pseudo-Obstruction in MELAS Using Acotiamide: A Case Report. *Case Rep Neurol*, Sep 14, 2024; 16(1):288-293. Doi: 10.1159/000541012
10. Mohammad M, Alsheikh K, Madlaji SE, Brimo Alsaman MZ. An Ogilvie's syndrome: A rare case of large bowel pseudo-obstruction. *Int J Emerg Med*, Mar 6, 2025; 18(1):46. Doi: 10.1186/s12245-025-00857-9